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a b s t r a c t
A large array of studies have investigated peripheral oxytocin (OT) and vasopressin (ADH) as potential
biomarkers of psychiatric disorders, with highly conflicting and heterogenous findings. We searched Web
of KnowledgeSM and Scopuss for English original articles investigating OT and/or ADH levels in different
biological fluids (plasma/serum, saliva, urine and cerebrospinal fluid) across several psychiatric disorders.
Sixty-four studies were included. We conducted 19 preliminary meta-analyses addressing OT alterations
in plasma/serum, saliva, urine and cerebrospinal fluid of 7 psychiatric disorders and ADH alterations in
plasma/serum, saliva, urine and cerebrospinal fluid of 6 psychiatric disorders compared to controls.
Hedge's g was used as effect size measure, together with heterogeneity analyses, test of publication
biases and quality control. None of them (except serum OT in anorexia nervosa) revealed significant
differences. There is no convincing evidence that peripheral ADH or OT might be reliable biomarkers in
psychiatric disorders. However, the lack of significant results was associated with high methodological
heterogeneity, low quality of the studies, small sample size, and scarce reliability of the methods used in
previous studies, which need to be validated and standardized.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Oxytocin (hereafter OT) and vasopressin (hereafter ADH) are
neuropeptides mainly synthesized in the brain’s hypothalamic
paraventricular (PVN) and supraoptic (SON) nuclei (Ludwig and
Leng, 2006). They are released in systemic circulation through the
posterior pituitary gland, where they act as hormones regulating a
range of physiological functions (Gimpl and Fahrenholz, 2001;
Leng et al., 2015). They are also released in the central nervous
system, acting on multiple brain regions as neuromodulators and
influencing a range of neurophysiological processes and beha-
viours (Stoop, 2012), including feeding, anxiety, aggression, social
recognition and the stress/fear response to social stimuli (Ha-
shimoto et al., 2012).
Evidence from animal studies has demonstrated the significant
role that OT and ADH play in the regulation of social behaviour and
cognition (Chang and Platt, 2014). An increasing number of studies
have also began to dissect the roles of OT and ADH in human social
behaviour (Heinrichs et al., 2009). These neuropeptides are asso-
ciated with complex social and emotional processing in healthy
people which if impaired may account for some of the symptoms
present in psychiatric disorders (Meyer-Lindenberg et al., 2011).
Furthermore, there is also growing interest in the potential for
synthetic neuropeptides in treatment of psychosis (for a compre-
hensive review see (Gumley et al., 2014)), autism spectrum dis-
orders (ASD) (Thompson et al., 2006; Uzunova et al., 2015), and
affective and anxiety disorders (Griebel et al., 2012).
In animals there are multiple methods that allow to reliably
either assess or manipulate central OT and ADH levels and their
effects on behaviour (e.g. intracerebral microdialysis (Veenema
and Neumann, 2008), targeted delivery of neuropeptide agonists
or antagonists (Song et al., 2014), gene knockout (Wersinger et al.,
2002), and viral gene transfer (Pagani et al., 2014)). However, these
are not available in humans, hence researchers have turned to
peripheral assays as proxy measures. Specifically, plasma/serum
(Rubin et al., 2014), saliva (Fujisawa et al., 2014), urine (Hoffman
et al., 2012) or cerebrospinal fluid (CSF) (Sasayama et al., 2012) OT
and ADH levels have been recently tested as putative biomarkers
in ASD (Alabdali et al., 2014; Boso et al., 2007; Modahl et al., 1998),
Psychosis (Elman et al., 2003; Goldman et al., 2008; Rubin et al.,
2013; Walss-Bass et al., 2013), bipolar disorder (BD) (Rubin et al.,
2014; Turan et al., 2013), major depressive disorder (MDD)
(Goldstein et al., 2000; Ozsoy et al., 2009; Yuen et al., 2014), as
well as in anxiety (Hoge et al., 2012, 2008), personality (Bertsch
et al., 2013) and eating disorders (anorexia nervosa, AN and buli-
mia nervosa, BN) (Frank et al., 2000; Lawson et al., 2011, 2012),
with highly heterogeneous and conflicting results (Al-Ayadhi,
2005; Alabdali et al., 2014; Emsley et al., 1989; Watson et al.,
2007). The first aim of the present systematic review and pre-
liminary meta-analysis was to test if the levels of these neuro-
peptides across different clinical samples and different biological
fluids (plasma/serum, cerebrospinal fluid (CSF), urine and saliva)
were consistently altered and could therefore be considered as
potential reliable biomarkers for psychiatric disorders. The second
aim was to investigate and address moderators and confounding
factors impacting the preliminary meta-analytical estimates.
2. Methods
2.1. Selection procedures and data collection
2.1.1. Search strategies
A systematic search strategy was used to identify relevant articles. A two-step
literature search was conducted by two independent researchers [GR, AS]. At a first
step, the Web of KnowledgeSM database by Thomson Reuterss (including Web of
Science™, BIOSIS Citation IndexSM and MEDLINEs) and Scopuss were searched.
The search was extended until March 1st, 2015, including abstracts in English
language only (see Supplementary materials for the electronic search code).
The second step involved the implementation of an electronic manual search of
the reference lists of the retrieved articles. Articles identified through these two
steps were then screened on basis of title or abstract reading. The articles surviving
selection were fully downloaded (PDFs) and assessed for eligibility on the basis of
full-text reading. Discrepancies were resolved through consensus with a third re-
searcher [MR]. To achieve high quality of reporting we adopted MOOSE guidelines
(Stroup et al., 2000) (see Supplementary materials).
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2.1.2. Inclusion criteria
Articles meeting the inclusion criteria for the current systematic review and
preliminary meta-analysis: (a) were original articles, written in English;
(b) included subjects with a psychiatric diagnosis defined according to interna-
tional standard definitions (ICD, DSM); c) included a healthy comparison group; d)
reported sufficient data on peripheral (plasma, serum, urine, cerebrospinal fluid,
saliva) OT or ADH level differences between groups (See Supplementary materials
for details).
2.1.3. Exclusion criteria
We excluded (a) abstracts, pilot datasets, reviews, articles in language other
than English; (b) articles failing to report enough data to perform a meta-analysis
(we also contacted the authors to obtain the missing data); (c) articles with over-
lapping datasets. In case of multiple publications deriving from the same study
population, we selected the articles reporting 1) the largest or 2) the most recent
data set. In case of conflict between these two criteria, the sample size was
prioritised.
2.1.4. Recorded variables
We recorded the following variables from each article: author, year of pub-
lication, quality of reporting criterion (adapted Newcastle-Ottawa Scale http://
www.ohri.ca/programs/clinical_epidemiology/oxford. asp, see Supplementary ma-
terial for detail), comparison group type (healthy comparisons), epidemiological
data of patient and control samples (baseline sample sizes, mean age, proportion of
females) and methodological information (specimen type, measurement method
(ELISA, RIA), plasma extraction (yes/no)).
For the peripheral level of OT and ADH measured in plasma/serum, saliva, urine
and CSF in patients and in controls, we extracted: mean value, standard deviation
(SD), and standard error of the mean (SEM) (when presented instead of SD). We
excluded data reporting OT or ADH peripheral levels following any drug
administration.
2.2. Statistical analysis
2.2.1. Effect size
The meta-analyses were performed using Comprehensive Meta-Analysis Soft-
ware version 2 (Borenstein et al., 2005). We did not perform analyses on diagnoses
where there was only one study available. As a measure of effect size, Hedges' g was
adopted. Results were Bonferroni-corrected for multiple testing, by dividing 0.05 by
the overall number of meta-analyses conducted.
2.2.2. Heterogeneity, publication biases, sensitivity analysis
Heterogeneity among study point estimates was assessed using Q statistics
(Paulson and Bazemore, 2010) and the proportion of the total variability in the
effect size estimates evaluated with the I2 index (Lipsey and Wilson, 2000). As
meta-analysis of observational studies is supposed to be characterized by sig-
nificant heterogeneity, random effect models were used (Cooper et al., 2009). Be-
cause of numerical constraints, meta-regressions were not conducted. Publication
biases were tested with the Duval and Tweedie “trim and fill” method (Duval and
Tweedie, 2000), when at least 3 studies were included. To further assess the ro-
bustness of the results, we performed sensitivity analyses by sequentially removing
each study and re-running the analysis, when at least 5 studies were included
(Higgins and Green, 2011). We conducted other sensitivity analyses to investigate
the putative influence of several categorical moderators: assay technique, preg-
nancy, alcohol use and phase of the psychotic disorder. In particular, we performed
sensitivity analyses to clarify the impact of peptide extraction techniques on the
results. Because of numerical constraints, this was possible only in two of the
subgroups (assessing plasma/serum ADH levels in MDD and psychosis). We per-
formed an additional sub-group analysis dividing First Episode Psychosis (FEP) and
chronic Psychosis vs healthy comparisons (see Supplementary materials for de-
tails). The potential influence of methodological weaknesses influencing pre-
liminary meta-analytic estimates, according to the quality rating, was discussed.
3. Results
3.1. Database
After manual and electronic searches, 192 potential articles
(PDFs) were screened to assess eligibility (see PRISMA flow chart
eFig. 1 and MOOSE checklist eTable 1). 52 articles were considered
eligible according to our inclusion criteria. 12 of these contributed
two individual samples each: six investigating both OT and ADH in
the same psychiatric disorder; four investigating the same neu-
ropeptide across two different psychiatric disorders; two
conducting the analyses on both plasma and CSF. Three articles
delivered four individual samples each: two by measuring OT and
ADH in two distinct diagnostic groups, and one measuring ADH
both in plasma and CSF in two psychiatric disorders. Finally, one
article delivered three individual samples, by addressing both
neuropeptides in BN and only OT in AN. Consequently, the total
number of eligible individual samples was 75. We did not perform
analyses on diagnoses where there was only one study available:
generalized social anxiety (GSAD) (Hoge et al., 2012), borderline
personality disorder (BPD) (Bertsch et al., 2013), attention deficit
and hyperactivity disorder (ADHD) (Taurines et al., 2014), Tourette
syndrome (TS) (Leckman et al., 1994) and Prader-Willi syndrome
(PWS) (Martin et al., 1998) (eTable 4). Therefore, the final database
included 64 samples. Further details of the eligible articles not
included in the meta-analysis and the list of the excluded articles
(with reason for exclusion) are given in eTables 4 and 5. The full
details of the included samples are appended in Table 1. The mean
sample size of the included samples was of 63.64 (736.50).
Overall we performed 19 preliminary meta-analyses.
3.2. Preliminary meta-analyses of OT peripheral levels in psychiatric
disorders
3.2.1. OT levels in CSF
Meta-analyses of OT levels in CSF were conducted in AN, BN, MDD,
OCD and Psychosis. We found no differences between healthy com-
parisons and AN (n¼2, overall sample¼52, Hedges' g¼"0.034, 95%
CI from "1.068 to 1.019, p unc¼0.950, between studies heterogeneity
non-significant), BN (n¼2, overall sample¼86, Hedges' g¼"0.219,
95% CI from "0.755 to 0.318, p unc¼0.425, between studies hetero-
geneity non-significant), MDD (n¼2, overall sample¼75, Hedges'
g¼"0.333, 95% CI from "0.781 to 0.114, p unc¼0.144, between
studies heterogeneity non-significant), Psychosis (n¼3, overall
sample¼147, Hedges' g¼0.287, 95% CI from "0.330 to 0.903, p
unc¼0.362, substantial between studies heterogeneity Q¼6.482,
I2¼69.14, p¼0.039), and OCD (n¼2, overall sample¼99, Hedges'
g¼0.599, 95% CI from 0.194 to 1.004, p unc¼0.004, p corr¼ns, be-
tween studies heterogeneity non-significant).
3.2.2. OT levels in plasma/serum
Meta-analyses of OT levels in plasma were conducted in ASD,
BD, Psychosis and AN. They revealed no difference between
healthy comparisons and patients diagnosed with ASD (n¼4,
overall sample¼404, Hedges' g¼"0.576, 95% CI from "1.442 to
0.291, p unc¼0.193, considerable between studies heterogeneity
Q¼64.613, I2¼93.81, po0.001), BD (n¼3, overall sample¼275,
Hedges' g¼0.056, 95% CI from "0.845 to 0.957, p unc¼0.903,
considerable between studies heterogeneity Q¼20.796, I2¼90.38,
po0.001) or Psychosis (n¼8, overall sample¼691, Hedges'
g¼"0.005, 95% CI from "0.304 to 0.294, p unc¼0.974, sub-
stantial between studies heterogeneity Q¼24.923, I2¼71.91,
p¼0.001). Patients with AN had lower serum OT levels than
healthy comparisons (n¼2, overall sample¼71, Hedges'
g¼"0.824, 95% CI from "1.308 to "0.341, p corr¼0.001, between
studies heterogeneity non-significant).
3.2.3. OT levels in saliva
Meta-analyses of OT levels in saliva were conducted in ADS. OT
levels in saliva of ASD were not statistically different from those
observed in healthy controls (n¼2, overall sample¼152, Hedges'
g¼"0.354, 95% CI from "0.701 to "0.006, p unc¼0.046, p corr¼
ns, between studies heterogeneity non significant).
3.2.4. OT levels in urine
Meta-analyses were not performed as insufficient data were
retrieved.
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Table 1
Characteristics of studies included in the meta-analysis.
Study name Year of publication Country Neuropeptide Specimen Diagnosis Sample size Age Female %
Total Pta HCb Pt HC Pt HC
Oxytocin in Autism Spectrum Disorders (7)
Modahl et al. (1998) 1998 USA OTc Plasma ASDd 59 29 30 8.1 8.8 0 0
(a) Al-Ayadhi (2005) 2005 Saudi Arabia OT Plasma ASD 154 77 77 8.8 0.08
(a) Miller et al. (2013) 2013 USA OT Plasma ASD 75 40 35 12 12.29 0.48 0.46
Alabdali et al. (2014) 2014 Saudi Arabia OT Plasma ASD 80 50 30 7 7.2 0 0
Feldman et al., (2014) 2014 Israel OT Saliva ASD 79 39 40 5.28 4.46 0.14 0.14
Fujisawa et al. (2014) 2014 Japan OT Saliva ASD 73 15 58 4.83 4.01 0.16 0.53
(a) Taurines et al. (2014) 2014 Germany OT Plasma ASD 36 19 17 10.7 13.6 0 0
Oxytocin in Bipolar Disorder (3)
Ozsoy et al. (2009) 2009 Turkey OT Serum BDe 43 11 32 39.78 0.63
Turan et al. (2013) 2013 Turkey OT Serum BD 91 67 24 34.63 34.42 0.46 0.41
(a) Rubin et al. (2014) 2014 USA OT Plasma BD 141 75 66 34.7 37.18 0.55 0.58
Oxytocin in Major Depressive Disorder (2)
(a) Pitts et al. (1995) 1995 USA OT CSFf MDDg 37 19 18 37.3 30.7 0.47 0.5
(a) Sasayama et al. (2012) 2012 Japan OT CSF MDD 38 17 21 39.5 38.3 0 0
Oxytocin in Psychosis (11)
(a) Beckmann et al. (1985) 1985 Germany OT CSF Psychosis 44 28 16 30.6 35 0 0.13
Glovinsky et al. (1994) 1994 USA OT CSF Psychosis 55 40 15 29 30 0.23 0.33
Goldman et al. (2008) 2008 USA OT Plasma Psychosis 22 15 7 40.88 34.7 0.6 0.43
Keri et al. (2009) 2009 Hungary OT Plasma Psychosis 100 50 50 47.9 47.8 0.68 0.68
Rubin et al. (2010) 2010 USA OT Serum Psychosis 108 50 58 30.94 27.73 0.46 0.54
(b) Sasayama et al. (2012) 2012 Japan OT CSF Psychosis 48 27 21 42.6 38.3 0 0
(a) Rubin et al. (2013) 2013 USA OT Serum Psychosis 76 38 38 23.71 27.89 0.37 0.37
Walss-Bass et al. (2013) 2013 USA OT Plasma Psychosis 80 60 20 42.1 39.65 0.25 0.3
(a) Jobst et al. (2014) 2014 Germany and Austria OT Plasma Psychosis 86 41 45 24.9 24.6 0 0
(b) Rubin et al. (2014) 2014 USA OT Plasma Psychosis 157 91 66 34.7 37.18 0.55 0.58
(a) Strauss et al. (2015) 2015 USA OT Plasma Psychosis 62 40 22 43.72 43.14 0.29 0.32
Oxytocin in Obsessive-Compulsive Disorder (2)
(a) Leckman et al.(1994) 1994 USA OT CSF OCDh 59 28 31 33.7 33 0.58 0.38
Altemus et al. (1999) 1999 USA OT CSF OCD 40 14 26 35.4 35 0.5 0.46
Oxytocin in Anorexia Nervosa (4)
(a) Demitrack et al. (1990) 1990 USA OT CSF ANi 25 14 11 24.3 25.5 1 1
(a) Frank et al. (2000) 2000 USA OT CSF AN 27 10 17 25.9 23.4 1 1
Lawson et al. (2011) 2011 USA OT Serum AN 36 17 19 27.7 27.5 1 1
Lawson et al. (2012) 2012 USA OT Serum AN 35 22 13 21.7 22 1 1
Oxytocin in Bulimia Nervosa (2)
(b) Demitrack et al. (1990) 1990 USA OT CSF BNj 46 35 11 24.4 25.5 1 1
(b) Frank et al. (2000) 2000 USA OT CSF BN 40 23 17 26.4 23.4 1 1
Antidiuretic Hormone in Autism Spectrum Disorder (3)
(b) Al-Ayadhi (2005) 2005 Saudi Arabia ADHk Plasma ASD 154 77 77 8.8 0.08
Boso et al. (2007) 2007 Italy ADH Plasma ASD 39 18 21 27.5 29.6 0.11 0.14
(b) Miller et al. (2013) 2013 USA ADH Plasma ASD 75 40 35 12 12.29 0.48 0.46
Antidiuretic Hormone in Bipolar Disorder (3)
Padfield et al. (1977) 1977 UK ADH Plasma BD 52 18 34 0.72
(c) Rubin et al. (2014) 2014 USA ADH Plasma BD 141 75 66 32.97 37.18 0.68 0.58
Antidiuretic Hormone in Major Depressive Disorder (6)
(a) Sorensen et al. (1985) 1985 Denmark ADH CSF MDD 98 46 52 46 46 0.74 0.58
(b) Sorensen et al. (1985) 1985 Denmark ADH Plasma MDD 98 46 52 46 46 0.74 0.58
(b) Pitts et al. (1995) 1995 USA ADH CSF MDD 37 19 18 37.3 30.7 0.47 0.50
Inder et al. (1997) 1997 New Zealand ADH Plasma MDD 56 45 11 32.5 32.5 0.6 0.63
Heuser et al. (1998) 1998 Germany ADH CSF MDD 62 37 25 46.8 65.5 0.7 0.32
van Londen et al. (1998) 1998 The Netherlands ADH Plasma MDD 89 52 37 44.8 41.2 0.57 0.54
Rubin et al. (1999) 1999 USA ADH Plasma MDD 40 20 20 40 38.44 0.6 0.6
Goldstein et al. (2000) 2000 USA ADH Plasma MDD 42 21 21 40 40 0.48 0.48
Goekoop et al. (2006) 2006 The Netherlands ADH Plasma MDD 98 81 17 40 0.67
Antidiuretic Hormone in Psychosis (13)
(b) Beckmann et al. (1985) 1985 Germany ADH CSF Psychosis 44 28 16 30.6 35 0 0.13
(c) Sorensen et al. (1985) 1985 Denmark ADH CSF Psychosis 61 9 52 29 46 0.33 0.58
(d) Sorensen et al. (1985) 1985 Denmark ADH Plasma Psychosis 61 9 52 29 46 0.33 0.58
Emsley et al. (1989) 1989 South Africa ADH Plasma Psychosis 51 23 28 0.30 0.25
Sarai and Matsunaga (1989) 1989 Japan ADH Plasma Psychosis 60 37 23 44.6 34 0.3 0.52
Ohsawa et al. (1993) 1993 Japan ADH Plasma Psychosis 30 15 15 32.2 27.3 0 0
Kudoh et al. (1998) 1998 Japan ADH Plasma Psychosis 40 18 22 54 55.2 0.56 0.59
Elman et al. (2003) 2003 USA ADH Plasma Psychosis 25 13 12 37.7 32.7 0.23 0.17
Ryan et al. (2004) 2004 UK ADH Plasma Psychosis 24 12 12 34.8 35.8 0.42 0.42
Walsh et al., (2005) 2005 Ireland ADH Plasma Psychosis 20 10 10 26.8 25 0 0
(b) Rubin et al. (2013) 2013 USA ADH Serum Psychosis 76 38 38 23.71 27.89 0.37 0.37
(b) Jobst et al. (2014) 2014 Germany and Austria ADH Plasma Psychosis 86 41 45 24.9 24.6 0 0
(d) Rubin et al. (2014) 2014 USA ADH Plasma Psychosis 157 91 66 35.31 37.18 0.39 0.58
Antidiuretic Hormone in Obsessive-Compulsive Disorder (2)
(a) Altemus et al. (1992b) 1992 USA ADH CSF OCD 40 15 25 34.3 31.3 0.53 0.48
(b) Leckman et al. (1994) 1994 USA ADH CSF OCD 59 28 31 33.7 33 0.58 0.38
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Overall effect sizes are depicted in Fig. 1(a), forest plots are
reported in supplementary materials (eFigs. 2 and 3) and eTable 6
report heterogeneity summary.
3.2.5. Publication biases and sensitivity analyses
The Duval and Tweedie's method showed that the results were
not affected by publication biases. Sensitivity analysis removing
one study per computation when at least 5 studies were included
confirmed the robustness of the results (Higgins and Green, 2011).
3.3. Preliminary meta-analyses of ADH peripheral levels in psy-
chiatric disorders
3.3.1. ADH levels in CSF
Meta-analyses of ADH levels in CSF were conducted in MDD,
Psychosis, AN and OCD. There were no differences between healthy
comparisons and patients diagnosed with MDD (n¼3, overall
sample¼197, Hedges' g¼"0.035, 95% CI from " .313 to 0.243, p
unc¼0.807, between studies heterogeneity non-significant), Psy-
chosis (n¼2, overall sample¼105, Hedges' g¼0.033, 95% CI from
"0.424 to 0.491, p unc¼0.886, between studies heterogeneity non-
significant), AN (n¼2, overall sample¼66, Hedges' g¼0.922, 95% CI
from 0.243 to 1.602, p unc¼0.008, p corr¼ ns, between studies
heterogeneity non significant) and OCD (n¼2, overall sample¼99,
Hedges' g¼0.601, 95% CI from 0.198 to 1.003, p unc¼0.003, p
corr¼ns, between studies heterogeneity non significant).
3.3.2. ADH levels in plasma/serum
Meta-analyses of ADH levels in plasma were conducted in ASD,
BD, AN, MDD and Psychosis.
There were no differences between healthy comparisons and
patients diagnosed with ASD (n¼3, overall sample¼268, Hedges'
g¼"0.086, 95% CI from "0.992 to 0.820, p unc¼0.853, con-
siderable between studies heterogeneity Q¼23.590, I2¼91.52,
po0.001), BD (n¼2, overall sample¼193, Hedges' g¼0.074, 95%
CI from "0.850 to 0.998, p unc¼0.875, considerable between
studies heterogeneity Q¼7.809, I2¼87.20, p¼0.005), AN (n¼2,
overall sample¼40, Hedges' g¼"0.479, 95% CI from "1.508 to
0.551, p unc¼0.362; between studies heterogeneity non-sig-
nificant), MDD (n¼6, overall sample¼423, Hedges' g¼"0.341,
95% CI from "0.078 to 0.759, p unc¼0.111, substantial between
studies heterogeneity Q¼19.078, I2¼73.79, po0.001), or Psy-
chosis (n¼11, overall sample¼630, Hedges' g¼"0.554, 95% CI
from "0.966 to "0.142, p unc¼0.008, p corr¼ns, considerable
between studies heterogeneity Q¼55.984, I2¼82.14, po0.001).
3.3.3. ADH levels in saliva and urine
Meta-analyses were not performed as insufficient data were
retrieved.
Overall effect sizes are depicted in Fig. 1(b), forest plots are
reported in Supplementary materials (eFigs. 4 and 5) and eTable 6
report heterogeneity summary.
3.3.4. Publication bias and sensitivity analyses
No significant publication bias emerged. In the MDD subgroup,
sensitivity analysis revealed that overall plasma level of ADH were
affected by inclusion of Sorensen et al. (1985). No significant dif-
ference emerged according to peptide extraction technique in
MDD (total between group heterogeneity Q¼0.021, df¼1,
p¼0.884).
On the contrary, in the Psychosis subgroup, sensitivity analysis
showed that the extraction technique could have an effect on the
observed results (total between group heterogeneity Q¼9.490,
df¼1, p¼0.002), in that ADH levels resulted significantly impaired
in Psychosis (n¼6, overall sample¼220, Hedges' g¼"1.099, 95%
CI from "1.617 to "0.581, p¼0.001, considerable between studies
heterogeneity Q¼13.626, I2¼63.31, p¼0.018) only in the group of
studies employing peptide extraction (see Fig. 2).
We also performed a sub-group analysis dividing First Episode
Psychosis (FEP) and chronic Psychosis vs healthy comparisons.
Three studies (Emsley et al., 1989; Rubin et al., 2013; Ryan et al.,
2004) investigated peripheral levels of ADH in first-episode, drug
naïve patients and eight (Beckmann et al., 1985; Elman et al.,
2003; Jobst et al., 2014; Kudoh et al., 1998; Ohsawa et al., 1993;
Rubin et al., 2014; Sarai and Matsunaga, 1989; Walsh et al., 2005)
in chronic patients. There was no significant between-group het-
erogeneity (Q¼6.228, df¼1, p unc¼0.013, p corr¼ns).
3.4. Quality assessment
Table 2 describes the quality of the studies. Study quality scores
ranged from 1 to 7 (median score was 4 out of 9 possible points).
There were no significant differences in Newcastle-Ottawa Scale
(NOS) scores between the subgroups (F¼0.503, df¼18, p¼0.943).
Unfortunately, since the number of studies included in each meta-
analysis was too small to perform meta-regressions, it was not
possible to directly assess the effect of NOS scores on the findings
of our preliminary meta-analyses.
Table 1 (continued )
Study name Year of publication Country Neuropeptide Specimen Diagnosis Sample size Age Female %
Total Pta HCb Pt HC Pt HC
Antidiuretic Hormone in Anorexia Nervosa (4)
(a) Gold et al. (1983) 1983 USA ADH CSF AN 16 8 8 24.3 25.3 1 1
(b) Gold et al. (1983) 1983 USA ADH Plasma AN 16 8 8 24.3 25.3 1 1
(c) Frank et al. (2000) 2000 USA ADH CSF AN 50 33 17 26.2 23.4 1 1
Evrard et al. (2004) 2004 Belgium ADH Plasma AN 24 12 12 21.6 22.8 1 1
a Pt, patients.
b HC, healthy controls.
c OT, oxytocin.
d ASD, autism spectrum disorder.
e BD, bipolar disorder.
f CSF, cerebrospinal fluid.
g MDD, major depressive disorder.
h OCD, obsessive-compulsive disorder.
i AN, anorexia nervosa.
j BN, bulimia nervosa.
k ADH, antidiuretic hormone.
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4. Discussion
This is the first systematic review and preliminary meta-ana-
lysis to comprehensively summarize the available evidence of al-
tered peripheral levels of OT and ADH in psychiatric disorders and
investigate whether there are reliable differences which could
serve as biomarkers between patients and healthy controls. We
found no robust and convincing evidence for significant alterations
in the two neuropeptides in psychiatric disorders.
The lack of significant association was secondary to high
heterogeneity across individual studies, low quality and significant
methodological limitations. Indeed, our results do not contradict
the potential role of the two neuropeptides in mental disorders
per se but do clearly suggest that peripheral levels do not reliably
distinguish cases from controls. The putative reasons for this will
be discussed in the following sections.
4.1. Reliability of assays
Both the commercially available immunoassays (RIA and EIA)
have high heterogeneity and questionable validity (McCullough
Fig. 1. Overall effect sizes for the comparison of OT and ADH levels in psychiatric patients vs healthy comparisons. Abbreviations: ADH, anti-diuretic hormone; AN, Anorexia
Nervosa; ASD, Autism Spectrum Disorder; BD, Bipolar Disorder; BN, Bulimia Nervosa; CSF, Cerebral-Spinal Fluid; MDD, Major Depressive Disorder; OCD, Obsessive Com-
pulsive Disorder; Pt, Patients. According to the Bonferroni correction, each hypothesis has been tested at a significance level of 0.002 (CI unadjusted). * po0.002.
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et al., 2013). Average plasmatic levels within studies included in
the present meta-analysis ranged from 0.64 pg/mL to
436.97 pg/mL for OT and from 0.66 pg/mL to 109.17 pg/mL for
ADH, this variability being massively explained by the use of dif-
ferent immunoassay and by whether or not a pre-assay sample
extraction was performed (eTable 2). It is evident, as others have
previously suggested (Christensen et al., 2014), that the two im-
munoassays are poorly correlated, thus preventing the comparison
of results obtained by different research groups. Particularly, in
recent evaluations the RIA method was shown to have low sen-
sitivity in the majority of samples tested (McCullough et al., 2013)
and EIA performed without extraction yielded to values that were
two orders of magnitude greater than those in extracted samples
(Szeto et al., 2011) and without correlation, due to the presence of
multiple adjunctive immunoreactive products besides oxytocin
(Szeto et al., 2011). Since the main methodological concern spe-
cifically regards the use of extraction (Christensen et al., 2014), we
performed a sensitivity analysis on the studies investigating ser-
um/plasma ADH levels in Psychosis, which seemed to confirm that
the extraction technique could have had an effect on the observed
results. However, further characterization of the tagged molecules
has shown that even in extracted samples the non-OT im-
munoreactive products of uncertain nature account for most of the
measured immunoreactivity (McCullough et al., 2013). With re-
spect to other bodily fluids, such as saliva and urine, it has been
demonstrated that the estimated levels are highly discrepant and
weakly correlated to plasmatic levels (McCullough et al., 2013).
4.2. Recommendations for methodological improvement
It is of crucial importance that future research in this field aim
at method validation and standardization before the results of
studies exploring the role of neuropeptides in physiology and
disease can be considered meaningful.
The samples obtained by EIA, even following the assay manu-
facturers’ recommendations to extract samples, contain multiple
non-OT immunoreactive molecules, still to identify. It is therefore
pivotal to clarify whether those are reflecting the turnover of
bioactive OT, or are non-related reactants. Moreover, assays with
high degree of sensitivity and specificity, such as two-dimensional
liquid chromatography separation with tandem mass spectro-
metry detection, could be used as reference for validation of
techniques as RIA and EIA and to confirm the presence of OT and
ADH in other biological fluids, such as saliva and urine, where less
knowledge is available.
Furthermore, pre-analytical errors should be avoided and sys-
tematic evaluation and standardization of pre-analytical proce-
dures should be conducted. In particular, consideration should be
payed to variations in the levels of the hormones related to cir-
cadian patterns and other physiological conditions (e. g., fasting or
post-prandial state, sexual activity, menstrual cycle, pregnancy),
time of day and environmental features during collection, tube
additives (e. g., EDTA and citrate), use of protease inhibitors and
storage conditions.
4.3. Peripheral vs central levels
Our results provide meta-analytical confirmation for the con-
cern, increasingly expressed by many authors, about the lack of
neurophysiological evidence of a direct relationship between
peripheral levels of OT and ADH and their central release and ac-
tivity (Grinevich et al., 2015; Kagerbauer et al., 2013; Leng and
Ludwig, 2015; Ludwig and Leng, 2006; McCullough et al., 2013;
Neumann, 2007). Originally, ADH and OT have been described as
hormones, involved respectively in antidiuresis, osmolality reg-
ulation, direct vasoconstriction and hepatic glycogenolysis (Ap-
pelgren, 1982; Robertson, 2001) and labor (Husslein, 1984), lacta-
tion (Crowley, 2015), and sexual activity (Carmichael et al., 1987).
Under physiological conditions, the primary drive for ADH per-
ipheral secretion is plasma osmolality. It is unlikely that this
homeostatic constraint can be chronically overridden by erratic
triggers, such as socioemotional stimuli (Kagerbauer et al., 2013).
Fig. 2. Plasma/serum ADH levels in psychotic patients vs healthy comparisons according to peptide extraction technique. Abbreviations: ADH, anti-diuretic hormone; Pt,
Patients. According to the Bonferroni correction, each hypothesis has been tested at a significance level of 0.002 (CI unadjusted).
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On the other hand plasma OT levels are stable, except in preg-
nancy (Leng and Ludwig, 2015), but may be regulated in-
dependently from central OT as suggested by converging evidence
from animal studies (Ludwig et al., 1994; Moos et al., 1989). In
humans no correlation was found between central and plasma OT
in pregnant women (Altemus et al., 2004) and suicide attempters
(Jokinen et al., 2012).
The mechanisms explaining such dissociation between central
and peripheral compartments are barely understood. Separate and
independent neuropeptide synthesis and vesicle routing and tar-
geting have been shown in the somata (for peripheral secretion
and somatic release) and in dendrites (for dendritic release),
which might account for independent central and peripheral re-
lease patterns (Landgraf and Neumann, 2004). The axons of the
magnocellular neurons (MCN) of the PVN and SON nuclei of the
hypothalamus project to the posterior pituitary from which they
can be secreted into the peripheral bloodstream to exert their
hormonal actions (Ludwig and Leng, 2006; Marazziti and Catena
Dell’osso, 2008). A substantial amount of ADH and OT are released
from soma and dendrites into the extracellular space, where the
neuropeptides act as autocrine or paracrine signals and diffuse
toward distant brain sites. The axons of the parvocellular neurons
of the PVN project centrally (Ludwig and Leng, 2006). Axonal and
dendritic/soma release may be independently regulated by the
MCNs through inhibitory mechanisms – mediated by corticoster-
one, GABA, endogenous opioids, the atrial natriuretic peptide and
ADH itself – which selectively block the peripheral secretion
(Wotjak et al., 1998).
The utility of CSF assays is more controversial. In fact, although
the extracellular fluid of the brain interconnects freely with the
CSF, the contribution of centrally released neuropeptides to CSF
levels depends on several factors, as they eventually reach the CSF
after having induced central effects by binding to specific re-
ceptors and having been possibly degraded by enzymes. It is
plausible that once diffused in the CSF, the neuropeptides may
have lost their biological activity, since they are unlikely to pass
back into the brain parenchyma against the concentration gradient
to act on their receptors. Furthermore, the blood-brain barrier
prevents ADH and OT to reflow into the central compartment (i. e.
brain parenchyma and CSF) once they have reached the peripheral
one (i. e., blood and peripheral organs) (Kagerbauer et al., 2013;
Mens et al., 1983). Further, peptides appear to have a short plasma
half-life (1–2 min) and a slightly longer central half-life (#30 min)
(MacDonald and MacDonald, 2010). Given to a positive feedback,
once dendritic release is triggered, it is self-sustaining and long-
lasting (Ludwig and Leng, 2006). Priming persisting for at least
90 min (Ludwig et al., 2002) allows peptides to survive for long
enough to diffuse to distant sites. Also long-lasting changes in-
duced in other transmitter systems may further extend their bio-
logical activity and behavioural effects (MacDonald and MacDo-
nald, 2010; Uvanas-Moberg et al., 2005).
4.4. Psychosis
Overall, we found no convincing evidence that either plasmatic
or CSF ADH and OT levels are altered in Psychosis. We also in-
vestigated whether the peripheral ADH impairments in Psychosis
were associated with the illness phase. It has been argued that
psychotic exacerbations may be concurrent with a transient reset
of the osmostasis for ADH secretion, elevated plasma levels of the
neuropeptide and eventually water imbalance, as an epipheno-
menon of dysfunctions in hypothalamic pituitary adrenal (HPA)
axis response to psychological stimuli (Goldman, 2009). However,
we found no meta-analytical evidence for peripheral ADH differ-
ences between first episode and chronic Psychosis.
Despite this findings should be interpreted in the light of a
body of literature that has demonstrated a role for these neuro-
peptides in functions which map on to common symptoms and
behavioural deficits in psychosis and schizophrenia, in particular
in the social cognition domain (MacDonald and MacDonald, 2010).
There is considerable evidence of a role these two neuropeptides
in various aspects of social behaviour. For example, OT alters re-
sponse to social cues (Zak et al., 2005) and has an effect on
emotion recognition/theory of mind (Domes et al., 2007; Guastella
et al., 2010b), fearful face processing (Evans et al., 2010), social
anxiety (Heinrichs et al., 2003), paranoia (Legros et al., 1992), and
trust behaviour (Baumgartner et al., 2008). Research with ADH in
human social cognition is less prevalent but there is evidence that
intranasal ADH biases emotional face perception (Thompson et al.,
2004)), enhances memory encoding of human faces (Guastella
et al., 2010b), produces gender-specific changes in perceived
friendliness of others, and alters autonomic response to threa-
tening faces (Thompson et al., 2006). ADH has been shown to alter
reciprocation of cooperation in males (Rilling et al., 2014) while
the ADH Avpr-1a gene, which is involved in social bonding in
humans (Walum et al., 2008), has been shown to influence the
money people will give to others in an economic game (Knafo
et al., 2008). As the present analysis investigates between-group
differences, not within-group effects our results do not contradict
the potential role of these neuropeptides in the symptoms of
psychosis per se. In schizophrenia, patients have been shown to
produce a failure in the trust-related increases in OT seen in
controls (Keri et al., 2009) and OT levels have been shown to
correlate inversely with symptomatology (including suspicious-
ness and paranoia) and prosociality (Rubin et al., 2010), as well as
capacity to identify facial emotions (Goldman et al., 2008). Neu-
roleptics have also been reported to normalise raised ADH plasma
levels in patients with schizophrenia (Raskind et al., 1987).
Furthermore, there is also emerging preclinical and clinical
evidence supporting the potential for manipulation by exogenous
delivery of these two neuropeptides. Administration of OT either
intracerebrally or subcutaneously effectively reverted behavioural
deficits in rodent models of schizophrenia (Macdonald and Feifel,
2012). Single-dose studies in humans proved OT ability to improve
the processing of emotional and social stimuli in subjects affected
by schizophrenia (MacDonald and MacDonald, 2010). Finally, the
results of two recent clinical trials of exogenous OT (intranasal
administration; dose: 24 IU twice daily (Pedersen et al., 2011) and
40 IU twice daily (Feifel et al., 2010)) in patients with schizo-
phrenia suggest a therapeutic effect across different symptom
domains with good safety and tolerability both in short-term and
long-lasting use. Nevertheless, a recent meta-analysis examining
the effects of OT on psychotic symptoms and social cognition
found weak and inconsistent evidence, mainly because of meth-
odological limitations, similarly as the ones observed by our cur-
rent analysis (Gumley et al., 2014).
4.5. ASD
We did not find evidence that peripheral ADH and OT levels are
impaired in ASD, in contrast with converging evidence from ani-
mal models of ASD and human studies which implicate alterations
in the function of the OT system within ASD. The results align with
concerns that these measures are not reliable proxies of the cen-
tral release and activity of these neuropeptides. In preclinical an-
imal models of neurodevelopmental disorders, autistic-like
symptoms were shown to be accounted by alterations of traffick-
ing and/or release of OT from axonal terminals and to be rescued
after OT administration (Grinevich et al., 2015). Clinical trials with
exogenous OT, administered either via intravenous infusion or
intranasal spray, have produced contradictory results, ranging
from positive outcomes in a variety of ASD psychopathology
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domains, namely emotion recognition (Guastella et al., 2010a),
social cognition (Andari et al., 2010), and core autistic repetitive
behaviours (e.g. ordering, compulsion to tell/ask and touching)
(Hollander et al., 2003), to modest (Anagnostou et al., 2012) or null
clinical improvement (Anagnostou et al., 2014). Although ADH is
less commercially available, the few reports to date show some
promise that ADH may exert gender-specific positive effects on
processes related to empathic ability (Thompson et al., 2006).
Nevertheless the findings in human studies should be interpreted
cautiously and confirmed in larger trials.
4.6. BD and MDD
Plasmatic and CSF neuropeptide levels were not significantly
altered in affective disorders (BD and MDD) compared to matched
healthy controls.
Again these results indicate that peripheral OT and ADH levels
are not reliable biomarkers of BD/MDD. In contrast to the null
findings shown here, several preclinical and clinical data provide
evidence of the association between ADH and affective disorders
(BD and MDD). ADH is involved in the regulation of the hy-
pothalamus-pituitary-adrenal (HPA) axis, which has been found to
be overactive in BD (Cervantes et al., 2001; Daban et al., 2005) and
MDD (Carroll et al., 1981; Dinan, 1994; Holsboer, 2000). Post-
mortem brain tissues of patients with MDD and BD contain a
greater number of ADH-immunoreactive neurons in the hy-
pothalamic PVN (Merali et al., 2006). Therefore, antagonists of V1b
receptor have been developed and tested in rodents as potential
new strategies for the treatment of affective disorders, whose ef-
ficacy in humans does still need clarification (Griebel et al., 2012).
4.7. OCD, AN and BN
Our meta-analysis did not detect significant alterations of ADH
and OT in OCD and BN. A difference in serum OT levels could be
observed between patients suffering from AN and healthy com-
parisons. The reliability of peripheral ADH and OT levels as bio-
markers of AN is weakened by the global hypothalamic-pituitary
dysfunction, the impact of fluid and sodium restriction and pur-
ging behaviours observed in AN and the putative role of the two
hormones in the regulation of the gut brain axis and energy
homeostasis (Blevins and Ho, 2013). In fact, both neuropeptide
levels end to be restored after body weight recovery (Gold et al.,
1983). Therefore, once again our findings should be interpreted
considering that peripheral levels of OT and ADH are unreliable
proxy measures of their central activity.
4.8. Limitations
There are some significant limitations to our study. The sub-
groups were very small in sample sizes. However, as re-
commended in the Cochrane Handbook for Systematic Reviews of
Interventions meta-analyses provide statistical combination of
results from two or more separate studies ((Higgins and Green,
2011), Chapter 9, page 244). The studies included were highly
heterogeneous. For example, despite evidence that patients with
schizoaffective psychoses may have clear distinctive features as
compared to schizophrenic psychoses (Pagel et al., 2013), they
were included in some of the articles in the Psychosis subgroup
(OT: 6 out of 11 (Goldman et al., 2008; Rubin et al., 2014, 2013,
2010; Strauss et al., 2015; Walss-Bass et al., 2013)); ADH (4 out of
13 (Emsley et al., 1989; Ohsawa et al., 1993; Rubin et al., 2014,
2013)). Correspondingly, psychotic features were unevenly con-
sidered as exclusion criteria across the articles investigating af-
fective disorders (BD and MDD). Several confounding factors
might have had an impact on the results. 38% of the included
studies reported that participants were taking lithium salts
(eTable 3). Despite its therapeutic value, lithium exerts adverse
effects on the kidney, leading to nephrogenic diabetes insipidus
(NDI) in up to 10% of the patients on long term treatment (Bendz
and Aurell, 1999; Bendz et al., 1996), which may be expected to be
associated with a compensatory increase in ADH release (Watson
et al., 2007). As regard OT, preclinical studies in rats found that a
systemic injection of lithium leads to a significant elevation of
peripheral OT levels (Cui et al., 2001; You et al., 2001). Further-
more, 42 studies out of 62 (68%) failed to control for alcohol intake
(not applicable to 2 studies which had recruited only children),
which was reported to induce degeneration in numerous neurons
in the hypothalamic magnocellular system in rats (Silva et al.,
2002). The majority of studies did not ascertain the pregnancy
state of female participants (70%, 35 out of 50, condition not ap-
plicable to 14 studies because of the characteristics of the sample,
see eTable 3 for further details). During pregnancy dramatic
structural and functional changes occur in the OT system of the
mother's brain (Hillerer et al., 2014; Rocchetti et al., 2014). More-
over, high levels of oxytocinase secreted by the placenta might
further contribute to the final serum/plasma OT levels (Nomura
et al., 2005). Finally, only 18% of the studies investigating OT and
none of those investigating ADH analyzed the fluctuations of OT
levels across the menstrual cycle phases. Studies investigating
plasma OT and ADH levels during the menstrual cycle in different
species, including humans, found that these fluctuate across the
ovarian cycle (Wathes and Swann, 1982). (Spruce et al., 1985). As a
consequence, our meta-analytical estimates are affected by high
uncertainty and should be considered as a preliminary synthesis of
the available literature.
5. Conclusions
The current meta-analysis does not provide convincing evi-
dence that peripheral OT or ADH levels are altered in psychiatric
disorders as compared to healthy controls. These findings are
characterized by high heterogeneity, various methodological lim-
itations, and poor quality. For more meaningful results to be ob-
tained, methods need to be validated and standardized. Future
studies are requested to better address with robust methods and
adequate sample sizes the actual role of ADH and OT as biomarkers
of mental illnesses.
Acknowledgements
The authors have declared that there are no conflicts of interest
in relation to the subject of this study. This work was supported
with the resources of the Department of Psychosis Studies; In-
stitute of Psychiatry, Psychology and Neuroscience; King's College
London, UK. Y.P. was supported in part by an ESRC fellowship
[Grant number ES/K009400/1]. Dr P.F.P. was supported in part by a
2014 NARSAD Young Investigator Award.
Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.psychres.2016.04.117.
References
Alabdali, A., Al-Ayadhi, L., El-Ansary, A., 2014. Association of social and cognitive
impairment and biomarkers in autism spectrum disorders. J. Neuroinflamm., 11.
G. Rutigliano et al. / Psychiatry Research 241 (2016) 207–220 217
Al-Ayadhi, L.Y., 2005. Altered oxytocin and vasopressin levels in autistic children in
Central Saudi Arabia. Neurosciences 10 (1), 47–50.
Altemus, M., Cizza, G., Gold, P.W., 1992a. Chronic fluoxetine treatment reduces
hypothalamic vasopressin secretion invitro. Brain Res. 593 (2), 311–313.
Altemus, M., Fong, J., Yang, R., Damast, S., Luine, V., Ferguson, D., 2004. Changes in
cerebrospinal fluid neurochemistry during pregnancy. Biol. Psychiatry 56 (6),
386–392.
Altemus, M., Pigott, T., Kalogeras, K.T., Demitrack, M., Dubbert, B., Murphy, D.L.,
Gold, P.W., 1992b. Abnormalities in the regulation of vasopressin and cortico-
tropin releasing-factor secretion in obsessive-compulsive disorder. Arch. Gen.
Psychiatry 49 (1), 9–20.
Altemus, M., Jacobson, K.R., Debellis, M., Kling, M., Pigott, T., Murphy, D.L., Gold, P.
W., 1999. Normal CSF oxytocin and NPY levels in OCD. Biol. Psychiatry 45 (7),
931–933.
Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., Jacob, S., 2014.
Intranasal oxytocin in the treatment of autism spectrum disorders: a review of
literature and early safety and efficacy data in youth. Brain Res. 1580, 188–198.
Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang,
A.T., Pepa, L., Tanel, N., Kushki, A., Hollander, E., 2012. Intranasal oxytocin versus
placebo in the treatment of adults with autism spectrum disorders: a rando-
mized controlled trial. Mol. Autism 3 (1), 16.
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., Sirigu, A., 2010. Pro-
moting social behavior with oxytocin in high-functioning autism spectrum
disorders. Proc. Natl. Acad. Sci. USA 107 (9), 4389–4394.
Appelgren, B., 1982. Reflex and hormonal influences on cerebral control of water-
balance – studies of alimentary and cardiovascular factors, and of systematic
angiotensin in the regulation of water-intake and adh secretion. Acta Physiol.
Scand., 1–39.
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., Fehr, E., 2008.
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans.
Neuron 58 (4), 639–650.
Beckmann, H., Lang, R.E., Gattaz, W.F., 1985. Vasopressin oxytocin in cerebrospinal-
fluid of schizophrenic-patients and normal controls. Psychoneuroendocrinol-
ogy 10 (2), 187–191.
Bendz, H., Aurell, M., 1999. Drug-induced diabetes insipidus: incidence, prevention
and management. Drug Saf. 21 (6), 449–456.
Bendz, H., Sjodin, I., Aurell, M., 1996. Renal function on and off lithium in patients
treated with lithium for 15 years or more. A controlled, prospective lithium-
withdrawal study. Nephrol. Dial. Transplant. 11 (3), 457–460.
Bertsch, K., Schmidinger, I., Neumann, I.D., Herpertz, S.C., 2013. Reduced plasma
oxytocin levels in female patients with borderline personality disorder. Horm.
Behav. 63 (3), 424–429.
Blevins, J.E., Ho, J.M., 2013. Role of oxytocin signaling in the regulation of body
weight. Rev. Endocr. Metab. Disord. 14 (4), 311–329.
Boso, M., Emanuele, E., Politi, P., Pace, A., Arra, M., di Nemi, S.U., Barale, F., 2007.
Reduced plasma apelin levels in patients with autistic spectrum disorder. Arch.
Med. Res. 38 (1), 70–74.
Carmichael, M.S., Humbert, R., Dixen, J., Palmisano, G., Greenleaf, W., Davidson, J.M.,
1987. Plasma oxytocin increases in the human sexual response. J. Clin. En-
docrinol. Metab. 64 (1), 27–31.
Carroll, B.J., Feinberg, M., Greden, J.F., Tarika, J., Albala, A.A., Haskett, R.F., James, N.
M., Kronfol, Z., Lohr, N., Steiner, M., de Vigne, J.P., Young, E., 1981. A specific
laboratory test for the diagnosis of melancholia. Standardization, validation,
and clinical utility. Arch. Gen. Psychiatry 38 (1), 15–22.
Cervantes, P., Gelber, S., Kin, F.N., Nair, V.N., Schwartz, G., 2001. Circadian secretion
of cortisol in bipolar disorder. J. Psychiatry Neurosci. 26 (5), 411–416.
Chang, S.W., Platt, M.L., 2014. Oxytocin and social cognition in rhesus macaques:
implications for understanding and treating human psychopathology. Brain
Res. 1580, 57–68.
Christensen, J.C., Shiyanov, P.A., Estepp, J.R., Schlager, J.J., 2014. Lack of association
between human plasma oxytocin and interpersonal trust in a prisoner’s di-
lemma paradigm. PLoS One 9 (12), e116172.
Cooper, H., Hedges, L., Valentine, J., 2009. Handbook of Research Synthesis and
Meta-Analysis. Russell Sage Foundation., New York, NY, USA.
Crowley, W.R., 2015. Neuroendocrine regulation of lactation and milk production.
Compr. Physiol. 5 (1), 255–291.
Cui, S.S., Bowen, R.C., Gu, G.B., Hannesson, D.K., Yu, P.H., Zhang, X., 2001. Prevention
of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic
neuronal activation. J. Neurosci. 21 (24), 9867–9876.
Daban, C., Vieta, E., Mackin, P., Young, A.H., 2005. Hypothalamic-pituitary-adrenal
axis and bipolar disorder. Psychiatr. Clin. N. Am. 28 (2), 469–480.
Demitrack, M.A., Lesem, M.D., Listwak, S.J., Brandt, H.A., Jimerson, D.C., Gold, P.W.,
1990. CSF oxytocin in anorexia-nervosa and bulimia-nervosa – clinical and
pathophysiologic considerations. Am. J. Psychiatry 147 (7), 882–886.
Dinan, T.G., 1994. Glucocorticoids and the genesis of depressive illness. A psycho-
biological model. Br. J. Psychiatry 164 (3), 365–371.
Domes, G., Heinrichs, M., Michel, A., Berger, C., Herpertz, S.C., 2007. Oxytocin im-
proves “mind-reading” in humans. Biol. Psychiatry 61 (6), 731–733.
Duval, S., Tweedie, R., 2000. Trim and fill: a simple funnel-plot-based method of testing
and adjusting for publication bias in meta-analysis. Biometrics 56 (2), 455–463.
Elman, I., Lukas, S., Shoaf, S.E., Rott, D., Adler, C., Breier, A., 2003. Effects of acute
metabolic stress on the peripheral vasopressinergic system in schizophrenia. J.
Psychopharmacol. 17 (3), 317–323.
Emsley, R., Potgieter, A., Taljaard, F., Joubert, G., Gledhill, R., 1989. Water-excretion
and plasma vasopressin in psychotic disorders. Am. J. Psychiatry 146 (2),
250–253.
Evans, S., Shergill, S.S., Averbeck, B.B., 2010. Oxytocin decreases aversion to angry
faces in an associative learning task. Neuropsychopharmacology 35 (13),
2502–2509.
Evrard, F., da Cunha, M.P., Lambert, M., Devuyst, O., 2004. Impaired osmoregulation
in anorexia nervosa: a case-control study. Nephrol. Dial. Transplant. 19 (12),
3034–3039.
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian,
A., Becker, O., Cooper, J., Perry, W., Lefebvre, M., Gonzales, J., Hadley, A., 2010.
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
Biol. Psychiatry 68 (7), 678–680.
Feldman, R., Golan, O., Hirschler-Guttenberg, Y., Ostfeld-Etzion, S., Zagoory-Sharon,
O., 2014. Parent child interaction and oxytocin production in pre-schoolers with
autism spectrum disorder. Br. J. Psychiatry 205 (2), 107–112.
Frank, G.K., Kaye, W.H., Altemus, M., Greeno, C.G., 2000. CSF oxytocin and vaso-
pressin levels after recovery from bulimia nervosa and anorexia nervosa, bu-
limic subtype. Biol. Psychiatry 48 (4), 315–318.
Fujisawa, T.X., Tanaka, S., Saito, D.N., Kosaka, H., Tomoda, A., 2014. Visual attention
for social information and salivary oxytocin levels in preschool children with
autism spectrum disorders: an eye-tracking study. Front. Neurosci. 8 295–295.
Gimpl, G., Fahrenholz, F., 2001. The oxytocin receptor system: structure, function,
and regulation. Physiol. Rev. 81 (2), 629–683.
Glovinsky, D., Kalogeras, K.T., Kirch, D.G., Suddath, R., Wyatt, R.J., 1994. Cere-
brospinal-fluid oxytocin concentration in schizophrenic-patients does not dif-
fer from control subjects and is not changed by neuroleptic medication. Schi-
zophr. Res. 11 (3), 273–276.
Goekoop, J.G., de Winter, R.P.F., de Rijk, R., Zwinderman, K.H., Frankhuijzen-Sier-
evogel, A., Wiegant, V.M., 2006. Depression with above-normal plasma vaso-
pressin: validation by relations with family history of depression and mixed
anxiety and retardation. Psychiatry Res. 141 (2), 201–211.
Gold, P.W., Kaye, W., Robertson, G.L., Ebert, M., 1983. Abnormalities in plasma and
cerebrospinal-fluid arginine vasopressin in patients with anorexia-nervosa. N.
Engl. J. Med. 308 (19), 1117–1123.
Goldman, M., Marlow-O’Connor, M., Torres, I., Carter, C.S., 2008. Diminished plasma
oxytocin in schizophrenic patients with neuroendocrine dysfunction and
emotional deficits. Schizophr. Res. 98 (1–3), 247–255.
Goldman, M.B., 2009. The mechanism of life-threatening water imbalance in
schizophrenia and its relationship to the underlying psychiatric illness. Brain
Res. Rev. 61 (2), 210–220.
Goldstein, G., Fava, M., Culler, M., Fisher, A., Rickels, K., Lydiard, R.B., Rosenbaum, J.,
2000. Elevated plasma thymopoietin associated with therapeutic nonrespon-
siveness in major depression. Biol. Psychiatry 48 (1), 65–69.
Griebel, G., Beeske, S., Stahl, S.M., 2012. The vasopressin V(1b) receptor antagonist
SSR149415 in the treatment of major depressive and generalized anxiety dis-
orders: results from 4 randomized, double-blind, placebo-controlled studies. J.
Clin. Psychiatry 73 (11), 1403–1411.
Grinevich, V., Knobloch-Bollmann, H.S., Eliava, M., Busnelli, M., Chini, B., 2015. As-
sembling the puzzle: pathways of oxytocin signaling in the brain. Biol.
Psychiatry.
Guastella, A.J., Kenyon, A.R., Alvares, G.A., Carson, D.S., Hickie, I.B., 2010b. Intranasal
arginine vasopressin enhances the encoding of happy and angry faces in hu-
mans. Biol. Psychiatry 67 (12), 1220–1222.
Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J., Lambert, T.J., Hickie,
I.B., 2010a. Intranasal oxytocin improves emotion recognition for youth with
autism spectrum disorders. Biol. Psychiatry 67 (7), 692–694.
Gumley, A., Braehler, C., Macbeth, A., 2014. A meta-analysis and theoretical critique
of oxytocin and psychosis: prospects for attachment and compassion in pro-
moting recovery. Br. J. Clin. Psychol. 53 (1), 42–61.
Hashimoto, H., Uezono, Y., Ueta, Y., 2012. Pathophysiological function of oxytocin
secreted by neuropeptides: a mini review. Pathophysiology: Off. J. Int. Soc.
Pathophysiol./ISP 19 (4), 283–298.
Heinrichs, M., von Dawans, B., Domes, G., 2009. Oxytocin, vasopressin, and human
social behavior. Front. Neuroendocrinol. 30 (4), 548–557.
Heinrichs, M., Baumgartner, T., Kirschbaum, C., Ehlert, U., 2003. Social support and
oxytocin interact to suppress cortisol and subjective responses to psychosocial
stress. Biol. Psychiatry 54 (12), 1389–1398.
Heuser, I., Bissette, G., Dettling, M., Schweiger, U., Gotthardt, U., Schmider, J.,
Lammers, C.H., Nemeroff, C.B., Holsboer, F., 1998. Cerebrospinal fluid con-
centrations of corticotropin-releasing hormone, vasopressin, and somatostatin
in depressed patients and healthy controls: response to amitriptyline treat-
ment. Depression Anxiety 8 (2), 71–79.
Hillerer, K.M., Jacobs, V.R., Fischer, T., Aigner, L., 2014. The maternal brain: an organ
with peripartal plasticity. Neural Plast. 2014, 574159.
Hoffman, E.R., Brownley, K.A., Hamer, R.M., Bulik, C.M., 2012. Plasma, salivary, and
urinary oxytocin in anorexia nervosa: a pilot study. Eat. Behav. 13 (3), 256–259.
Hoge, E.A., Pollack, M.H., Kaufman, R.E., Zak, P.J., Simon, N.M., 2008. Oxytocin levels
in social anxiety disorder. CNS Neurosci. Ther. 14 (3), 165–170.
Hoge, E.A., Lawson, E.A., Metcalf, C.A., Keshaviah, A., Zak, P.J., Pollack, M.H., Simon,
N.M., 2012. Plasma oxytocin immunoreactive products and response to trust in
patients with social anxiety disorder. Depression Anxiety 29 (11), 924–930.
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C.M., Aronowitz, B.R.,
Mosovich, S., 2003. Oxytocin infusion reduces repetitive behaviors in adults
with autistic and Asperger’s disorders. Neuropsychopharmacology 28 (1),
193–198.
Holsboer, F., 2000. The corticosteroid receptor hypothesis of depression. Neu-
ropsychopharmacology 23 (5), 477–501.
Husslein, P., 1984. [The importance of oxytocin and prostaglandins to the
G. Rutigliano et al. / Psychiatry Research 241 (2016) 207–220218
mechanism of labor in humans]. Wien. Klin. Wochenschr. Suppl. 155, 1–32.
Inder, W.J., Donald, R.A., Prickett, T.C.R., Frampton, C.M., Sullivan, P.F., Mulder, R.T.,
Joyce, P.R., 1997. Arginine vasopressin is associated with hypercortisolemia and
suicide attempts in depression. Biol. Psychiatry 42 (8), 744–747.
Higgins, J.P.T., Green, S., 2011. Cochrane Handbook for Systematic Reviews of In-
terventions, Version 5.1.0 ed. The Cochrane Collaboration.
Jobst, A., Dehning, S., Ruf, S., Notz, T., Buchheim, A., Henning-Fast, K., Meissner, D.,
Meyer, S., Bondy, B., Muller, N., Zill, P., 2014. Oxytocin and vasopressin levels are
decreased in the plasma of male schizophrenia patients. Acta Neuropsychiatr.
26 (6), 347–355.
Jokinen, J., Chatzittofis, A., Hellstrom, C., Nordstrom, P., Uvnas-Moberg, K., Asberg,
M., 2012. Low CSF oxytocin reflects high intent in suicide attempters. Psycho-
neuroendocrinology 37 (4), 482–490.
Kagerbauer, S.M., Martin, J., Schuster, T., Blobner, M., Kochs, E.F., Landgraf, R., 2013.
Plasma oxytocin and vasopressin do not predict neuropeptide concentrations in
human cerebrospinal fluid. J. Neuroendocrinol. 25 (7), 668–673.
Keri, S., Kiss, I., Kelemen, O., 2009. Sharing secrets: oxytocin and trust in schizo-
phrenia. Soc. Neurosci. 4 (4), 287–293.
Knafo, A., Israel, S., Darvasi, A., Bachner-Melman, R., Uzefovsky, F., Cohen, L., Feld-
man, E., Lerer, E., Laiba, E., Raz, Y., Nemanov, L., Gritsenko, I., Dina, C., Agam, G.,
Dean, B., Bornstein, G., Ebstein, R.P., 2008. Individual differences in allocation of
funds in the dictator game associated with length of the arginine vasopressin
1a receptor RS3 promoter region and correlation between RS3 length and
hippocampal mRNA. Genes Brain Behav. 7 (3), 266–275.
Kudoh, A., Kudo, M., Ishihara, H., Matsuki, A., 1998. Increased plasma vasopressin
and atrial natriuretic peptide in chronic schizophrenic patients during ab-
dominal surgery. Neuropsychobiology 37 (4), 169–174.
Landgraf, R., Neumann, I.D., 2004. Vasopressin and oxytocin release within the
brain: a dynamic concept of multiple and variable modes of neuropeptide
communication. Front. Neuroendocrinol. 25 (3–4), 150–176.
Lawson, E.A., Donoho, D.A., Blum, J.I., Meenaghan, E.M., Misra, M., Herzog, D.B.,
Sluss, P.M., Miller, K.K., Klibanski, A., 2011. Decreased nocturnal oxytocin levels
in anorexia nervosa are associated with low bone mineral density and fat mass.
J. Clin. Psychiatry 72 (11), 1546–1551.
Lawson, E.A., Holsen, L.M., Santin, M., Meenaghan, E., Eddy, K.T., Becker, A.E., Her-
zog, D.B., Goldstein, J.M., Klibanski, A., 2012. Oxytocin secretion is associated
with severity of disordered eating psychopathology and insular cortex hy-
poactivation in anorexia nervosa. J. Clin. Endocrinol. Metab. 97 (10),
E1898–E1908.
Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., Pauls, D.L.,
Anderson, G.M., Riddle, M.A., McSwigganhardin, M., McDougle, C.J., Barr, L.C.,
Cohen, D.J., 1994. Elevated cerebrospinal-fluid levels of oxytocin in obsessive-
compulsive disorder – comparison with tourettes-syndrome and healthy con-
trols. Arch. Gen. Psychiatry 51 (10), 782–792.
Legros, J.J., Ansseau, M., Swaab, D.F., Saper, C.B., Kremer, H.P.H., Dewied, D., 1992.
Neurohypophyseal peptides and psychopathology, in: Swaab, D.F., Hofman, M.
A., Mirmiran, M., Ravid, R., Vanleeuwen, F.W. (Eds.), Human Hypothalamus in
Health and Disease, pp. 455–461.
Leng, G., Ludwig, M., 2015. Intranasal oxytocin: myths and delusions. Biol.
Psychiatry.
Leng, G., Pineda Reyes, R., Sabatier, N., Ludwig, M., 2015. The posterior pituitary:
from Geoffrey Harris to our present understanding. J. Endocrinol.
Lipsey, M., Wilson, D., 2000. Practical Meta-Analysis. Sage Publications, Thousand
Oaks, CA.
Ludwig, M., Leng, G., 2006. Dendritic peptide release and peptide-dependent be-
haviours. Nat. Rev. Neurosci. 7 (2), 126–136.
Ludwig, M., Callahan, M.F., Neumann, I., Landgraf, R., Morris, M., 1994. Systemic
osmotic stimulation increases vasopressin and oxytocin release within the
supraoptic nucleus. J. Neuroendocr. 6 (4), 369–373.
Ludwig, M., Sabatier, N., Bull, P.M., Landgraf, R., Dayanithi, G., Leng, G., 2002. In-
tracellular calcium stores regulate activity-dependent neuropeptide release
from dendrites. Nature 418 (6893), 85–89.
Borenstein, M.H.L., Higgins, J., Rothstein, H, 2005. Comprehensive Meta-Analysis
Version 2. Biostat, Englewood, NJ, USA.
Macdonald, K., Feifel, D., 2012. Oxytocin in schizophrenia: a review of evidence for
its therapeutic effects. Acta Neuropsychiatr. 24 (3), 130–146.
MacDonald, K., MacDonald, T.M., 2010. The peptide that binds: a systematic review
of oxytocin and its prosocial effects in humans. Harv. Rev. Psychiatry 18 (1),
1–21.
Marazziti, D., Catena Dell’osso, M., 2008. The role of oxytocin in neuropsychiatric
disorders. Curr. Med. Chem. 15 (7), 698–704.
Martin, A., State, M., Anderson, G.M., Kaye, W.M., Hanchett, J.M., McConaha, C.W.,
North, W.G., Leckman, J.F., 1998. Cerebrospinal fluid levels of oxytocin in Pra-
der-Willi syndrome: a preliminary report. Biol. Psychiatry 44 (12), 1349–1352.
McCullough, M.E., Churchland, P.S., Mendez, A.J., 2013. Problems with measuring
peripheral oxytocin: can the data on oxytocin and human behavior be trusted?
Neurosci. Biobehav. Rev. 37 (8), 1485–1492.
Mens, W.B., Witter, A., van Wimersma Greidanus, T.B., 1983. Penetration of neurohy-
pophyseal hormones from plasma into cerebrospinal fluid (CSF): half-times of dis-
appearance of these neuropeptides from CSF. Brain Res. 262 (1), 143–149.
Merali, Z., Kent, P., Du, L., Hrdina, P., Palkovits, M., Faludi, G., Poulter, M.O., Bedard,
T., Anisman, H., 2006. Corticotropin-releasing hormone, arginine vasopressin,
gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain
regions of suicides and control subjects. Biol. Psychiatry 59 (7), 594–602.
Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M., 2011. Oxytocin and va-
sopressin in the human brain: social neuropeptides for translational medicine.
Nat. Rev. Neurosci. 12 (9), 524–538.
Miller, M., Bales, K.L., Taylor, S.L., Yoon, J., Hostetler, C.M., Carter, C.S., Solomon, M.,
2013. Oxytocin and vasopressin in children and adolescents with autism
spectrum disorders: sex differences and associations with symptoms. Autism
Res. 6 (2), 91–102.
Modahl, C., Green, L., Fein, D., Morris, M., Waterhouse, L., Feinstein, C., Levin, H.,
1998. Plasma oxytocin levels in autistic children. Biol. Psychiatry 43 (4),
270–277.
Moos, F., Poulain, D.A., Rodriguez, F., Guerne, Y., Vincent, J.D., Richard, P., 1989.
Release of oxytocin within the supraoptic nucleus during the milk ejection
reflex in rats. Exp. Brain Res. 76 (3), 593–602.
Neumann, I.D., 2007. Stimuli and consequences of dendritic release of oxytocin
within the brain. Biochem. Soc. Trans. 35 (Pt 5), 1252–1257.
Nomura, S., Ito, T., Yamamoto, E., Sumigama, S., Iwase, A., Okada, M., Shibata, K.,
Ando, H., Ino, K., Kikkawa, F., Mizutani, S., 2005. Gene regulation and physio-
logical function of placental leucine aminopeptidase/oxytocinase during preg-
nancy. Biochim. Biophys. Acta 1751 (1), 19–25.
Ohsawa, H., Kishimoto, T., Shimayoshi, N., Matsumura, K., Tahara, K., Kitera, K.,
Higashiura, N., Noriyama, Y., Matsumoto, H., Hirai, M., Ikawa, G., 1993. Atrial-
natriuretic-peptide and arginine-vasopressin secretion in schizophrenic-pa-
tients. Acta Psychiatr. Scand. 88 (2), 130–134.
Ozsoy, S., Esel, E., Kula, M., 2009. Serum oxytocin levels in patients with depression
and the effects of gender and antidepressant treatment. Psychiatry Res. 169 (3),
249–252.
Padfield, P.L., Park, S.J., Morton, J.J., Braidwood, A.E., 1977. Plasma-levels of anti-
diuretic-hormone in patients receiving prolonged lithium-therapy. Br. J. Psy-
chiatry 130, 144–147.
Pagani, J.H., Zhao, M., Cui, Z., Williams Avram, S.K., Caruana, D.A., Dudek, S.M.,
Young, W.S., 2014. Role of the vasopressin 1b receptor in rodent aggressive
behavior and synaptic plasticity in hippocampal area CA2. Mol. Psychiatry.
Pagel, T., Baldessarini, R.J., Franklin, J., Baethge, C., 2013. Characteristics of patients
diagnosed with schizoaffective disorder compared with schizophrenia and bi-
polar disorder. Bipolar Disord. 15 (3), 229–239.
Paulson, J.F., Bazemore, S.D., 2010. Prenatal and postpartum depression in fathers
and its association with maternal depression: a meta-analysis. JAMA 303 (19),
1961–1969.
Pedersen, C.A., Gibson, C.M., Rau, S.W., Salimi, K., Smedley, K.L., Casey, R.L., Leser-
man, J., Jarskog, L.F., Penn, D.L., 2011. Intranasal oxytocin reduces psychotic
symptoms and improves theory of mind and social perception in schizo-
phrenia. Schizophr. Res. 132 (1), 50–53.
Pitts, A.F., Samuelson, S.D., Meller, W.H., Bissette, G., Nemeroff, C.B., Kathol, R.G.,
1995. Cerebrospinal-fluid corticotropin-releasing hormone, vasopressin, and
oxytocin concentrations in treated patients with major depression and controls.
Biol. Psychiatry 38 (5), 330–335.
Raskind, M.A., Courtney, N., Murburg, M.M., Backus, F.I., Bokan, J.A., Ries, R.K., Dorsa,
D.M., Weitzman, R.E., 1987. Antipsychotic-drugs and plasma vasopressin in
normals and acute schizophrenic-patients. Biol. Psychiatry 22 (4), 453–462.
Rilling, J.K., Demarco, A.C., Hackett, P.D., Chen, X., Gautam, P., Stair, S., Haroon, E.,
Thompson, R., Ditzen, B., Patel, R., Pagnoni, G., 2014. Sex differences in the
neural and behavioral response to intranasal oxytocin and vasopressin during
human social interaction. Psychoneuroendocrinology 39, 237–248.
Robertson, G.L., 2001. Antidiuretic hormone. Normal and disordered function. En-
docrinol. Metab. Clin. N. Am. 30 (3), 671–694 (vii).
Rocchetti, M., Radua, J., Paloyelis, Y., Xenaki, L.A., Frascarelli, M., Caverzasi, E., Politi,
P., Fusar-Poli, P., 2014. Neurofunctional maps of the ‘maternal brain’ and the
effects of oxytocin: a multimodal voxel-based meta-analysis. Psychiatry Clin.
Neurosci. 68 (10), 733–751.
Rubin, L.H., Carter, C.S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J.A., Maki, P.M.,
2010. Peripheral oxytocin is associated with reduced symptom severity in
schizophrenia. Schizophr. Res. 124 (1–3), 13–21.
Rubin, L.H., Carter, C.S., Bishop, J.R., Pournajafi-Nazarloo, H., Harris, M.S.H., Hill, S.K.,
Reilly, J.L., Sweeney, J.A., 2013. Peripheral vasopressin but not oxytocin relates
to severity of acute psychosis in women with acutely-ill untreated first-episode
psychosis. Schizophr. Res. 146 (1–3), 138–143.
Rubin, L.H., Carter, C.S., Bishop, J.R., Pournajafi-Nazarloo, H., Drogos, L.L., Hill, S.K.,
Ruocco, A.C., Keedy, S.K., Reilly, J.L., Keshavan, M.S., Pearlson, G.D., Tamminga, C.
A., Gershon, E.S., Sweeney, J.A., 2014. Reduced levels of vasopressin and reduced
behavioral modulation of oxytocin in psychotic disorders. Schizophr. Bull. 40
(6), 1374–1384.
Rubin, R.T., O’Toole, S.M., Rhodes, M.E., Sekula, L.K., Czambel, R.K., 1999. Hypotha-
lamo-pituitary-adrenal cortical responses to low-dose physostigmine and ar-
ginine vasopressin administration: sex differences between major depressives
and matched control subjects. Psychiatry Res. 89 (1), 1–20.
Ryan, M.C.M., Sharifi, N., Condren, R., Thakore, J.H., 2004. Evidence of basal pitui-
tary-ad renal overactivity in first episode, drug naive patients with schizo-
phrenia. Psychoneuroendocrinology 29 (8), 1065–1070.
Sarai, M., Matsunaga, H., 1989. ADH secretion in schizophrenic-patients on anti-
psychotic-drugs. Biol. Psychiatry 26 (6), 576–580.
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., Arima, K., Higuchi,
T., Amano, N., Kunugi, H., 2012. Negative correlation between cerebrospinal
fluid oxytocin levels and negative symptoms of male patients with schizo-
phrenia. Schizophr. Res. 139 (1–3), 201–206.
Silva, S.M., Madeira, M.D., Ruela, C., Paula-Barbosa, M.M., 2002. Prolonged alcohol
intake leads to irreversible loss of vasopressin and oxytocin neurons in the
paraventricular nucleus of the hypothalamus. Brain Res. 925 (1), 76–88.
Song, Z., McCann, K.E., McNeill, J.Kt, Larkin 2nd, T.E., Huhman, K.L., Albers, H.E.,
G. Rutigliano et al. / Psychiatry Research 241 (2016) 207–220 219
2014. Oxytocin induces social communication by activating arginine-vaso-
pressin V1a receptors and not oxytocin receptors. Psychoneuroendocrinology
50, 14–19.
Sorensen, P.S., Gjerris, A., Hammer, M., 1985. Cerebrospinal-fluid vasopressin in
neurological and psychiatric-disorders. J. Neurol. Neurosurg. Psychiatry 48 (1),
50–57.
Spruce, B.A., Baylis, P.H., Burd, J., Watson, M.J., 1985. Variation in osmoregulation of
arginine vasopressin during the human menstrual-cycle. Clin. Endocrinol. 22
(1), 37–42.
Stoop, R., 2012. Neuromodulation by oxytocin and vasopressin. Neuron 76 (1),
142–159.
Strauss, G.P., Keller, W.R., Koenig, J.I., Gold, J.M., Frost, K.H., Buchanan, R.W., 2015.
Plasma oxytocin levels predict social cue recognition in individuals with schi-
zophrenia. Schizophr. Res. 162 (1–3), 47–51.
Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher,
D., Becker, B.J., Sipe, T.A., Thacker, S.B., 2000. Meta-analysis of observational
studies in epidemiology: a proposal for reporting. Meta-analysis Of observa-
tional studies in epidemiology (MOOSE) group. JAMA 283 (15), 2008–2012.
Szeto, A., McCabe, P.M., Nation, D.A., Tabak, B.A., Rossetti, M.A., McCullough, M.E.,
Schneiderman, N., Mendez, A.J., 2011. Evaluation of enzyme immunoassay and
radioimmunoassay methods for the measurement of plasma oxytocin. Psy-
chosom. Med. 73 (5), 393–400.
Taurines, R., Schwenck, C., Lyttwin, B., Schecklmann, M., Jans, T., Reefschlager, L.,
Geissler, J., Gerlach, M., Romanos, M., 2014. Oxytocin plasma concentrations in
children and adolescents with autism spectrum disorder: correlation with
autistic symptomatology. Atten. Deficit Hyperact. Disord. 6 (3), 231–239.
Thompson, R., Gupta, S., Miller, K., Mills, S., Orr, S., 2004. The effects of vasopressin
on human facial responses related to social communication. Psychoneur-
oendocrinology 29 (1), 35–48.
Thompson, R.R., George, K., Walton, J.C., Orr, S.P., Benson, J., 2006. Sex-specific in-
fluences of vasopressin on human social communication. Proc. Natl. Acad. Sci.
USA 103 (20), 7889–7894.
Turan, T., Uysal, C., Asdemir, A., Kilic, E., 2013. May oxytocin be a trait marker for
bipolar disorder? Psychoneuroendocrinology 38 (12), 2890–2896.
Uvanas-Moberg, K., Arn, I., Magnusson, D., 2005. The psychobiology of emotion: the
role of the oxytocinergic system. Int. J. Behav. Med. 12 (2), 59–65.
Uzunova, G., Pallanti, S., Hollander, E., 2015. Excitatory/inhibitory imbalance in
autism spectrum disorders: Implications for interventions and therapeutics.
World J. Biol. Psychiatry, 1–13.
van Londen, L., Kerkhof, G.A., van den Berg, F., Goekoop, J.G., Zwinderman, K.H.,
Frankhuijzen-Sierevogel, A.C., Wiegant, V.M., de Wied, D., 1998. Plasma argi-
nine vasopressin and motor activity in major depression. Biol. Psychiatry 43 (3),
196–204.
Veenema, A.H., Neumann, I.D., 2008. Central vasopressin and oxytocin release:
regulation of complex social behaviours. Prog. Brain Res. 170, 261–276.
Walsh, P., Spelman, L., Sharifi, N., Thakore, J.H., 2005. Mate patients with paranoid
schizophrenia have greater ACTH and cortisol secretion in response to meto-
clopramide-induced AVP release. Psychoneuroendocrinology 30 (5), 431–437.
Walss-Bass, C., Fernandes, J.M., Roberts, D.L., Service, H., Velligan, D., 2013. Differ-
ential correlations between plasma oxytocin and social cognitive capacity and
bias in schizophrenia. Schizophr. Res. 147 (2–3), 387–392.
Walum, H., Westberg, L., Henningsson, S., Neiderhiser, J.M., Reiss, D., Igl, W., Ga-
niban, J.M., Spotts, E.L., Pedersen, N.L., Eriksson, E., Lichtenstein, P., 2008. Ge-
netic variation in the vasopressin receptor 1a gene (AVPR1A) associates with
pair-bonding behavior in humans. Proc. Natl. Acad. Sci. USA 105 (37),
14153–14156.
Wathes, D.C., Swann, R.W., 1982. Is oxytocin an ovarian hormone? Nature 297
(5863), 225–227.
Watson, S., Gallagher, P., Smith, M.S., Young, A.H., Ferrier, I.N., 2007. Lithium, ar-
ginine vasopressin and the dex/CRH test in mood disordered patients. Psy-
choneuroendocrinology 32 (5), 464–469.
Wersinger, S.R., Ginns, E.I., O’Carroll, A.M., Lolait, S.J., Young 3rd, W.S., 2002. Va-
sopressin V1b receptor knockout reduces aggressive behavior in male mice.
Mol. Psychiatry 7 (9), 975–984.
Wotjak, C.T., Ganster, J., Kohl, G., Holsboer, F., Landgraf, R., Engelmann, M., 1998.
Dissociated central and peripheral release of vasopressin, but not oxytocin, in
response to repeated swim stress: new insights into the secretory capacities of
peptidergic neurons. Neuroscience 85 (4), 1209–1222.
You, Z.D., Li, J.H., Song, C.Y., Lu, C.L., He, C., 2001. Oxytocin mediates the inhibitory
action of acute lithium on the morphine dependence in rats. Neurosci. Res. 41
(2), 143–150.
Yuen, K.W., Garner, J.P., Carson, D.S., Keller, J., Lembke, A., Hyde, S.A., Kenna, H.A.,
Tennakoon, L., Schatzberg, A.F., Parker, K.J., 2014. Plasma oxytocin concentra-
tions are lower in depressed vs. healthy control women and are independent of
cortisol. J. Psychiatr. Res. 51, 30–36.
Zak, P.J., Kurzban, R., Matzner, W.T., 2005. Oxytocin is associated with human
trustworthiness. Horm. Behav. 48 (5), 522–527.
G. Rutigliano et al. / Psychiatry Research 241 (2016) 207–220220
